Research Article
Volume 14 Issue 5 - 2022
Parkinson’s Disease and Dementia with Lewy Bodies, Patients Under Treatment with Standardized Extracts Enriched in Cannabidiol and Cannabigerol: Descriptive Observations in Preparation for a Phase 2a Clinical Trial

Flávio Henrique de Rezende Costa1,2*, Simone Pellegrino1, Mariana Spitz3, Eduardo Rydz1, Gabriel de Castro Micheli1, Elio Tanaka4, Brian Michael Ebner5, Jaron Gladstone5 and Andrew J Lees6

1Health Meds Laboratories, Rio de Janeiro, Brazil

2Multidisciplinary Clinic, Botagofo, Rio de Janeiro, Brazil

3Estate University of Rio de Janeiro, Brazil

4TNK, Curitiba- Brazil

5CBCeuticals, Coral Springs, Flórida, USA

6Queen Square Brain Bank for Neurological Disorders, University College London Queen Square Institute of Neurology, London, UK

*Corresponding Author: Flávio Henrique de Rezende Costa, Health Meds Laboratories, Rio de Janeiro and Multidisciplinary Clinic, Botagofo, Rio de Janeiro, Brazil.
Received: December 29, 2021; Published: April 26, 2022


Background: Cannabis-based formulations are now widely used by patients with neurological and psychiatric problems but no studies have been published on the clinical utility of CBD/CBG enriched extracts for parkinsonism's symptoms.

Objectives: To describe preliminary clinical data collection of PD and DLB patients under CBD/CBG medical prescription.

Methods: Review of electronic records of 14 PD and 5 DLB patients. Four extracts were available 1) CBD broad spectrum (100 mg/mL) 2) CBD/CBG broad spectrum (100 mg/mL 2:1) (3) CBD/CBG (2:1) + THC0.3% full spectrum (100mg/mL) 4) CBD+THC0.3% full spectrum (100 mg/mL). All the patients received authorization from ANVISA (Brazil) to import the formulations for medical use. Outcomes of each unmet need (UMN) were tabulated and graded.

Results: Demographics: PD N = 14 (10 male). DLB: N = 5 (3 male). Mean age: PD: 76.2 yrs. (46 - 94). DLB: 82.2 yrs. (83 - 92). Disease duration: PD (6.57 yrs.), DLB (4.2 yrs.); PD H/Y stage (3); PD levodopa dose: 490 mg (150 - 900). Mean daily doses: PD CBD: 65.17 mg (8.33 – 125 mg), CBG: 22,50 mg (4.16 - 50 mg), THC: 2,32 mg (0,75 - 4,5 mg). DLB CBD: 52 mg (5 - 100 mg). CBG: 8,75 mg (2,5 - 15 mg), THC: 0,225 mg. Positive results were seen for RBD, insomnia, anxiety, and pain. All pain responders were on CBG and/or THC formulations. Hallucinations were also attenuated in both patient groups. Safety and tolerability were favorable in this small sample.

Conclusions: Future clinical trials in Parkinson’s disease and DLB with cannabinoids should focus on their potential benefit for associated anxiety, and pain. The potential anti-psychotic effects of CBD and CBD/CBG  should also be further evaluated in a phase 2a clinical trial.


Keywords: Cannabidiol; Cannabigerol; Parkinson’s Disease; Dementia With Lewy Bodies; Medical Cannabis


  1. Goetz CG. “The History of Parkinson’s Disease: Early Clinical Descriptions and Neurological Therapies”. Cold Spring Harbor Perspectives in Medicine1 (2011): a008862-a008862.
  2. Russo EB. “History of cannabis and its preparations in saga, science, and sobriquet”. Chemistry and Biodiversity8 (2007): 1614-1648.
  3. “History of cannabis as a medicine: a review”. The Revista Brasileira de Psiquiatria (2006).
  4. Gaoni Y and Mechoulam R. “Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish”. Journal of the American Chemical Society8 (1964): 1646-1647.
  5. Mechoulam R. “Marihuana chemistry”. Science3936 (1970): 1159-1166.
  6. Matsuda LA., et al. “Structure of a cannabinoid receptor and functional expression of the cloned cDNA”. Nature6284 (1990): 561-564.
  7. Munro S., et al. “Molecular characterization of a peripheral receptor for cannabinoids”. Nature6441 (1993): 61-65.
  8. Cristino L., et al. “Cannabinoids and the expanded endocannabinoid system in neurological disorders”. Nature Reviews Neurology1 (2020): 9-29.
  9. McPartland JM., et al. “Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review”. British Journal of Pharmacology 172 (2015): 737-753.
  10. De Petrocellis L., et al. “Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes”. British Journal of Pharmacology7 (2011): 1479-1494.
  11. Russo EB., et al. “Agonistic properties of cannabidiol at 5-HT1a receptors”. Neurochemical Research8 (2005): 1037-1043.
  12. Rylander D., et al. “Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: Effects on motor behavior and striatal nuclear signaling”. Journal of Pharmacology and Experimental Therapeutics1 (2009): 227-235.
  13. Leweke FM., et al. “Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia”. Translational Psychiatry3 (2012).
  14. Nachnani R., et al. “The Pharmacological Case For Cannabigerol (Cbg)”. Journal of Pharmacology and Experimental Therapeutics (2020).
  15. O’Sullivan SE. “An update on PPAR activation by cannabinoids”. British Journal of Pharmacology 173 (2016): 1899-1910.
  16. Ryz NR., et al. “Cannabis Roots: A Traditional Therapy with Future Potential for Treating Inflammation and Pain”. Cannabis and Cannabinoid Research1 (2017): 210-216.
  17. Ligresti A., et al. “Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma”. Journal of Pharmacology and Experimental Therapeutics3 (2006): 1375-1387.
  18. García C., et al. “Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s disease: Possible involvement of different binding sites at the PPARγ receptor”. Journal of Neuroinflammation1 (2018).
  19. Díaz-Alonso J., et al. “VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington’s disease”. Scientific Reports (2016): 6.
  20. Russo EB., et al. “Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms”. Cannabis and Cannabinoid Research (2021).
  21. Perras C. “Sativex for the management of multiple sclerosis symptoms”. Issues in Emerging Health Technologies 72 (2005): 1-4.
  22. Devinsky O., et al. “Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome”. The New England Journal of Medicine21 (2017): 2011-2020.
  23. RDC 327 (2019).
  24. RDC 318 (2019).
  25. RDC 335 (2020).
  26. MH C., et al. “Effects of Cannabidiol in the Treatment of Patients With Parkinson’s Disease: An Exploratory Double-Blind Trial”. Journal of Psychopharmacology11 (2014).
  27. Zuardi AW., et al. “Cannabidiol for the treatment of psychosis in Parkinson’s disease”. Journal of Psychopharmacology8 (2009): 979-983.
  28. Chagas MHN., et al. “Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series”. Journal of Clinical Pharmacy and Therapeutics5 (2014): 564-566.
  29. Frankel JP., et al. “Marijuana for Parkinsonian tremor”. Journal of Neurology Neurosurgery and Psychiatry 53(1990): 436.
  30. KA S., et al. “Cannabinoids Reduce Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Pilot Study”. Neurology11 (2001).
  31. Crippa JAS., et al. “Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms?” European Archives of Psychiatry and Clinical Neuroscience1 (2019): 121-133.
  32. McGuire P., et al. “Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial”. The American Journal of Psychiatry3 (2018): 225-231.
  33. Sellers EM., et al. “A Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group QT/QTc Study to Evaluate the Electrophysiologic Effects of THC/CBD Spray”. Clinical Pharmacology in Drug Development3 (2013): 285-294.
  34. Hughes AJ., et al. “Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases”. Journal of Neurology, Neurosurgery, and Psychiatry3 (1992): 181-184.
  35. Hughes AJ., et al. “Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases”. Journal of Neurology, Neurosurgery, and Psychiatry3 (1992): 181-184.
  36. Viktor B., et al. “Pathological and clinical comparison of Parkinson’s disease dementia and dementia with Lewy bodies”. Orvosi Hetilap18 (2020): 727-737.
  37. Murillo-Rodríguez E., et al. “Systemic Injections of Cannabidiol Enhance Acetylcholine Levels from Basal Forebrain in Rats”. Neurochemical Research8 (2018): 1511-1518.
  38. De Almeida CMO., et al. “Pharmacological treatment for REM sleep behavior disorder in Parkinson disease and related conditions: A scoping review”. Journal of the Neurological Sciences (2018): 393.
  39. Seppala LJ., et al. “Fall-Risk-Increasing Drugs: A Systematic Review and Meta-Analysis: II. Psychotropics”. Journal of the American Medical Directors Association4 (2018): 371.e11-371.e17.
  40. Russo EB. “The Case for the Entourage Effect and Conventional Breeding of Clinical Cannabis: No and quot;Strain, and quot; No Gain”. Frontiers in Plant Science 9 (2018): 1969.
  41. Kempster PA., et al. “Relationships between age and late progression of Parkinson’s disease: a clinico-pathological study”. Brain6 (2010): 1755-1762.
Citation: Flávio Henrique de Rezende Costa., et al. “Parkinson’s Disease and Dementia with Lewy Bodies, Patients Under Treatment with Standardized Extracts Enriched in Cannabidiol and Cannabigerol: Descriptive Observations in Preparation for a Phase 2a Clinical Trial”. EC Neurology 14.5 (2022): 01-15.

PubMed Indexed Article

EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005

EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777

EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347

EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478

EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253

EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033

EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992

EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505

EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793

EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211

EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047

EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560

EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318

EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819

EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840

EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344

EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476

EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658

EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489

EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278

EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108

EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571

EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333

EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883

EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001

EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937

EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723

EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726

EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603

EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646

EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616

EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290

EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226

EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812

EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268

News and Events

June Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the June issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for Upcoming Issue

ECronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before July 14, 2022.

Certificate of Publication

ECronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

ECronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.